



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



شبكة المعلومات الجامعية

التوثيق الالكتروني والميكرو فيلم

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم



نقسم بـلله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد اعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



شبكة المعلومات الجامعية



بالرسالة صفحات

لم ترد بالأصل

مستقر بحجج كيرة
2-4
1-9
1-6
B1.1111



TRIPLE THERAPY IN THE TREATMENT OF
HELICOBACTER PYLORI INFECTION AND ITS EFFECTS
ON GASTRIC AND DUODENAL DISORDERS

M. Sc. thesis Submitted in partial fulfillment of master degree
In internal Medicine

By

AHMAD AMIN IBRAHIM

Resident Of internal medicine

Faculty of Medicine, El- Minia University

Under Supervision of

PROF. DR. ANWAR MOHAMMAD ORIEBY

Professor and head of Internal Medicine Department
Faculty of Medicine, El- Minia University

PROF. DR. WAFAA AREF

Professor of Pathology
Faculty of Medicine, El- Minia University

DR. MOHAMMAD EMAD ABDEL-FATTAH

Lecturer of Internal Medicine
Faculty of Medicine, El- Minia University

Faculty of Medicine, El- Minia University

2000 G. - 1421H.

الذين هم يملكونهم بالانطواء
يا ابيهم

We will
catch your
M-Pylori
definitely



Contents

	Pag
*List of contents.....	i
*List of abbreviations	iv
*List of Tables.....	v
*List of Figures	vi
*Acknowledgment	viii
*Introduction and aim of the work.....	1
*Review of the Literature	3
→ ANATOMICAL AND HISTOLOGICAL CONSIDERATIONS OF STOMACH AND DUODENUM.....	3
Anatomy of the Stomach.....	3
Anatomy of the Duodenum	5
→ PHYSIOLOGICAL CONSIDERATIONS OF THE STOMACH AND DUODENUM	8
Regulation of gastric secretion.....	9
Acetylcholine and gastrin hormone.....	9
Histamine.....	12
Pepsin.....	12
Maintenance of normal mucosal integrity.....	13
Gastric mucus.....	13
Bicarbonate.....	14
Mucosal blood flow.....	14
Cell renewal	15
Endogenous prostaglandin	15

→ 4/EPIDEMIOLOGY OF HELICOBACTER PYLORI INFECTION.....	16
- Routes of transmission.....	16
(1) Oral-oral spread.....	16
(2) Fecal-oral spread.....	17
(3) Iatrogenic spread.....	17
(4) Vectors.....	18
Risk factors for H. pylori- associated disease.....	18
(1) Microbial virulence gene.....	18
(2) Environmental and social factors.....	19
(3) Host genetics	20
Helicobacter pylori factors associated with disease development.....	22
(1) Colonization.....	22
(2) Avoidance of immune response.....	23
(3) Damage to the host.....	23
 BACTERIOLOGICAL CONSIDERATION AND DIAGNOSIS OF	
HELICOBACTER PYLORI ORGANISM	24
	24
Unique feature of H. pylori.	24
Location of H. pylori:.....	24
Staining.....	26
Culture.....	29
Polymerase chain reaction (PCR).....	30
Serological examination.....	31
Rapid Urease test.....	32
Urea breath tests (UBTs).....	33
 PATHOLOGIC DISORDERS ASSOCIATED WITH H. PYLORI	
INFECTION.....	36
Non-ulcer dyspepsia (NUD).....	38
Chronic gastritis.....	39
Gastro- duodenal ulceration.....	43
Gastro- oesophageal reflux disease (GORD).....	51
Hypochlorhydria.....	53
Gastric cancer.....	54
Mucosa associated lymphoid tissue (MALT) lymphoma.....	56

-Role of Helicobacter pylori in other diseases.....	57
Enteric fever.....	57
Childhood disease.....	57
Pernicious anaemia.....	58
Atherosclerosis.....	58
→ TREATMENT OF H. PYLORI INFECTION.....	59
Treatment goals.....	60
(1) Simplicity.....	60
(2) Tolerability.....	60
(3) Compliance.....	61
(4) Efficacy.....	62
Regimens under investigation to treat H. pylori infection.....	62
Regimens used for treatment (eradication) of H. pylori infection.....	62
Monotherapy.....	63
Dual therapy.....	64
Triple therapy.....	65
Quadruple therapy.....	68
Resistance to antibiotics.....	69
Resistance to macrolides	69
Resistance to metronidazole.....	70
Who should be treated for Helicobacter pylori infection?.....	72
Vaccination for Helicobacter Pylori.....	71
Therapeutic considerations	75
Therapeutic considerations	76
* Subject and Methods	79
* Results.....	11
* Discussion.....	12
* Summary, conclusions and recommendations.....	13
* References.....	14
* Arabic Summary.....	17

List of Abbreviations

*DU.....	Duodenal Ulcer
*FDA.....	Food and Drug Administration
*GORD.....	Gastro-Oesophageal Reflux Disease
*H. pylori.....	Helicobacter pylori
*H2RAs.....	Histamine Receptors Antagonists
*MALT- Lymphoma.....	Mucosa Associated Lymphoid Tissue Lymphoma
*MIC.....	Minimum Inhibitory Concentration
*NSAIDs.....	Non-Steroidal Anti-Inflammatory Drugs
*NUD.....	Non-Ulcer Dyspepsia
*PPIs.....	Proton Pump Inhibitors
*PU	Peptic ulcer
*RBC	Ranitidine Bismuth Citrate

List of Figures

	Page
Figure (1): H. pylori by Electron microscope.....	25
Figure (2): Histology slide (Giemsa stain) showing H. pylori.....	28
Figure (3): Gram stain showing gram-negative bacilli.....	28
Figure(4): Histology slide (Warthin-Starry) showing H. pylori...	28
Figure (5): Principle of urease test - - - - -	32
Figure (6): Slide of the CLO test	35
Figure (7): ¹³ C- Urea breath test	35
Figure (8): Principle of urea breath test.....	35
Figure (9): Endoscopic finding of Gastritis	41
Figure (10) Endoscopic finding of Gastropathy.....	41
Figure (11) Endoscopic appearance of duodenitis.....	41
Figure(12) Endoscopic appearance of gastric ulcer.....	46
Figure(13) Endoscopic appearance of duodenal ulcer.....	46
Figure(14): Figure showing floor of peptic ulcer.....	47
Figure(15): Figure showing histopathology of duodenitis.....	47
Figure (16) Figure showing histopathology of gastritis.....	47
Figure (17) Histological of acute gastric ulcer showing destruction of all mucosal thickness.....	121
Figure (18) Chronic atrophic gastritis in mucosa of the body of the stomach.....	121
Figure(19) H. pylori-associated chronic superficial gastritis . - - -	121

المنزل
المنزل
المنزل

List of Tables

→ Page

Table (1):	Protein-based calibrators tubes for radioimmunoassay of serum gastrin.	91
Table (2):	Clinical findings in Lanzoprazole patients (group A).....	101
Table (3):	Laboratory findings in Lanzoprazole patients (group A)...	103
Table (4):	Sonographic findings in Lanzoprazole patients (group A).	104
Table (5):	Endoscopic findings in Lanzoprazole patients (group A)..	104
Table (6):	Gastric biopsy in Lansoprazole patients (group A).....	104
Table(7):	Side effects observed during eradication therapy in Lansoprazole patients (group A).....	105
Table (8):	Clinical findings in Ranitidine hydrochloride patients (group B).....	106
Table (9):	Laboratory findings in Ranitidine hydrochloride patients (group B).....	108
Table (10):	Sonographic findings in Ranitidine hydrochloride patients (group II).....	109
Table (11):	Endoscopic findings in Ranitidine hydrochloride patients (group B).....	110
Table (12):	Gastric biopsy in Ranitidine hydrochloride patients (group B).....	110
Table (13):	Side effects observed during eradication therapy in Ranitidine patients (group B).....	110
Table (14):	Serum gastrin level among both groups.....	111
Table(15):	Clinical outcome of patients after 4 and 8 weeks.....	123
Table(16):	Correlation between eradication and healing.....	124
Table(17):	Comparison between the endoscopic findings between the two groups after the therapy.	124
Table(18):	Urease test and Histopathological examination in both groups after the therapy.....	124
Table(19):	Comparison between the endoscopic findings between before and after the therapy in group A.....	125
Table(20):	Comparison between the endoscopic findings between before and after the therapy in group B.....	125

Table(21):

Table(21): Side effects observed during the two regimens of eradication..... 127

ACKNOWLEDGMENT